The field of cannabinoid research is advancing, with new discoveries being made about the potential therapeutic benefits of these compounds. However, for these discoveries to be translated into effective treatments for patients, it is essential that proper due diligence is done, and well-designed clinical trials programs are initiated.

In this presentation from the recent International Cannabis Business Conference in Berlin, Terry O’Regan, President of Brains Bioceutical, discusses the course, challenges, considerations, and rewards for advancing the cannabinoid scientific research landscape.

We look forward to seeing you in Berlin in 2024, as well as at our upcoming science and technology event in Slovenia this September!